EATG » Hepatitis

Hepatitis

Tenofovir disoproxil fumarate for nucleos(t)ide analog-resistant chronic HBV

In patients with chronic hepatitis B (CHB) that is resistant to multiple nucleos(t)ide analogs (NUCs), long-term tenofovir disoproxil fumarate (TDF) monotherapy provided a virologic response in most, but it was…

What do people who inject drugs think of point-of-care HCV testing?

Point-of-care testing to diagnose HCV infection has the potential to eliminate the need for multiple appointments to confirm chronic infection. An oral antibody test can provide a result in 20…

Widespread testing, treatment of hepatitis C in US prisons improves outcomes

BOSTON -- At current drug prices, testing all persons entering prison for Hepatitis C, treating those who have at least 12 months remaining in their sentence, and linking individuals with…

Direct-acting agents for hepatitis C reduce risk for incident diabetes

In a large cohort of patients with hepatitis C virus (HCV), the use of direct-acting antiviral agents (DAA) was associated with significantly lower incidence and risk for subsequent diabetes, according…

Identifying Organ Donor Risk Factors Increases Recipient HBV, HCV Survival

For organ recipients with donor-derived hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, recognizing risk factors among organ donors may contribute to early diagnosis and treatment, according to…

Risk for Liver Cancer Associated With HCV-Induced Epigenetic Changes

Epigenetic and gene expression alterations associated with risk for hepatocellular carcinoma (HCC) have been identified in an analysis of liver tissue obtained from patients with hepatitis C virus (HCV) infection,…

Dicerna announces dosing of first patient in Phase 1 clinical trial of DCR-HBVS for the treatment of hepatitis B

Clinical proof-of-concept data expected in fourth quarter of 2019 CAMBRIDGE, Mass., May 16, 2019 -- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid…

EGALITE study confirms efficacy of elbasvir/grazoprevir for patients with HCV, mild fibrosis

Results from the EGALITE study showed that 12 weeks of elbasvir/grazoprevir was a highly effective regimen for treatment-naive Asian patients with hepatitis C virus genotype 1b infection and mild liver…

Approximately 12 million ROL allocated to the National Framework Plan for Viral Hepatitis Control in Romania for the period 2019-2030

The Ministry of Health (MoH) launched the National Framework Plan for Viral Hepatitis Control in Romania for the period 2019-2030. It aims to reduce the prevalence of viral hepatitis as…

Access to hepatitis C testing and treatment for people who inject drugs and people in prisons — a global perspective

The World Health Organization (WHO) released a policy brief on access to HCV testing and treatment for people who inject drugs and for people in prisons (April 2019). Overview WHO…

1 5 6 7 8 9 116